Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001079973-13-000318
Filing Date
2013-05-07
Accepted
2013-05-07 16:17:27
Documents
10
Period of Report
2013-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q FOR THE PERIOD ENDED 3/31/2013 appy_10q-033113.htm 10-Q 581239
2 EXHIBIT 31.1 ex31x1.htm EX-31.1 11410
3 EXHIBIT 31.2 ex31x2.htm EX-31.2 11552
4 EXHIBIT 32 ex32.htm EX-32 9089
  Complete submission text file 0001079973-13-000318.txt   4434254

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE FILE appy-20130331.xml EX-101.INS 593559
6 XBRL SCHEMA FILE appy-20130331.xsd EX-101.SCH 40647
7 XBRL CALCUALTION FILE appy-20130331_cal.xml EX-101.CAL 34761
8 XBRL DEFINITION FILE appy-20130331_def.xml EX-101.DEF 158454
9 XBRL LABEL FILE appy-20130331_lab.xml EX-101.LAB 516766
10 XBRL PRESENTATION FILE appy-20130331_pre.xml EX-101.PRE 251400
Mailing Address 1585 S. PERRY STREET CASTLE ROCK CO 80104
Business Address 1585 S. PERRY STREET CASTLE ROCK CO 80104 (303) 794-2000
Venaxis, Inc. (Filer) CIK: 0001167419 (see all company filings)

EIN.: 841553387 | State of Incorp.: CO | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33675 | Film No.: 13820228
SIC: 2835 In Vitro & In Vivo Diagnostic Substances